X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA CIPLA AJANTA PHARMA/
CIPLA
 
P/E (TTM) x 28.3 44.3 64.0% View Chart
P/BV x 11.7 3.9 302.3% View Chart
Dividend Yield % 0.5 0.3 154.6%  

Financials

 AJANTA PHARMA   CIPLA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
CIPLA
Mar-17
AJANTA PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,720622 276.6%   
Low Rs1,103458 240.7%   
Sales per share (Unadj.) Rs194.6181.9 107.0%  
Earnings per share (Unadj.) Rs45.212.9 351.3%  
Cash flow per share (Unadj.) Rs50.329.3 171.6%  
Dividends per share (Unadj.) Rs8.002.00 400.0%  
Dividend yield (eoy) %0.60.4 153.1%  
Book value per share (Unadj.) Rs132.0155.7 84.8%  
Shares outstanding (eoy) m88.77804.51 11.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.33.0 244.2%   
Avg P/E ratio x31.242.0 74.4%  
P/CF ratio (eoy) x28.118.4 152.3%  
Price / Book Value ratio x10.73.5 308.2%  
Dividend payout %17.715.5 113.8%   
Avg Mkt Cap Rs m125,299434,516 28.8%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m2,57026,338 9.8%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m17,275146,302 11.8%  
Other income Rs m1662,287 7.3%   
Total revenues Rs m17,442148,589 11.7%   
Gross profit Rs m5,80724,758 23.5%  
Depreciation Rs m45113,229 3.4%   
Interest Rs m491,594 3.1%   
Profit before tax Rs m5,47412,222 44.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4601,798 81.2%   
Profit after tax Rs m4,01410,354 38.8%  
Gross profit margin %33.616.9 198.6%  
Effective tax rate %26.714.7 181.3%   
Net profit margin %23.27.1 328.3%  
BALANCE SHEET DATA
Current assets Rs m7,63987,370 8.7%   
Current liabilities Rs m2,71533,081 8.2%   
Net working cap to sales %28.537.1 76.8%  
Current ratio x2.82.6 106.5%  
Inventory Days Days4387 49.7%  
Debtors Days Days7962 126.3%  
Net fixed assets Rs m6,914111,567 6.2%   
Share capital Rs m1771,609 11.0%   
"Free" reserves Rs m11,442123,645 9.3%   
Net worth Rs m11,721125,254 9.4%   
Long term debt Rs m14936,454 0.4%   
Total assets Rs m14,814209,532 7.1%  
Interest coverage x112.98.7 1,302.9%   
Debt to equity ratio x00.3 4.4%  
Sales to assets ratio x1.20.7 167.0%   
Return on assets %27.45.7 481.0%  
Return on equity %34.28.3 414.3%  
Return on capital %46.58.5 547.4%  
Exports to sales %55.134.2 161.2%   
Imports to sales %6.08.3 72.0%   
Exports (fob) Rs m9,52750,050 19.0%   
Imports (cif) Rs m1,03812,203 8.5%   
Fx inflow Rs m10,42251,066 20.4%   
Fx outflow Rs m1,67817,678 9.5%   
Net fx Rs m8,74433,388 26.2%   
CASH FLOW
From Operations Rs m3,26423,824 13.7%  
From Investments Rs m-2,093-13,127 15.9%  
From Financial Activity Rs m-1,186-13,239 9.0%  
Net Cashflow Rs m-15-2,478 0.6%  

Share Holding

Indian Promoters % 73.8 16.0 461.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 1.6 12.2 12.7%  
FIIs % 7.6 23.7 32.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.0 26.2 64.9%  
Shareholders   20,968 161,166 13.0%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  VENUS REMEDIES  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS